WHITEHAWK THERAPEUTICS, INC. Revenue
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $7.14M, a 72.50% decline from fiscal 2024.
- WHITEHAWK THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $25.98M, a 6.69% increase from fiscal 2023.
- WHITEHAWK THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $24.35M, a 60.06% increase from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $15.22M, a 8.69% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 1 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $7.14M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $7.14M 10-Q · filed 2025-11-06 | $14.38M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $7.14M 10-Q · filed 2026-08-06 | $14.38M derived: sum of 3 quarters · filed 2026-08-06 | $21.60M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $7.14M 10-Q · filed 2026-05-07 | $14.38M derived: sum of 2 quarters · filed 2026-05-07 | $21.60M derived: sum of 3 quarters · filed 2026-05-07 | $27.77M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $7.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $14.45M derived: sum of 2 quarters · filed 2026-03-12 | $20.63M derived: sum of 3 quarters · filed 2026-03-12 | $25.98M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $7.21M 10-Q · filed 2025-11-06 | $13.39M derived: sum of 2 quarters · filed 2025-11-06 | $18.74M 10-Q · filed 2025-11-06 | $25.07M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $6.18M 10-Q · filed 2025-08-07 | $11.53M 10-Q · filed 2025-08-07 | $17.86M derived: sum of 3 quarters · filed 2025-08-07 | $23.82M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $5.35M 10-Q · filed 2025-05-08 | $11.68M derived: sum of 2 quarters · filed 2025-05-08 | $17.64M derived: sum of 3 quarters · filed 2025-05-08 | $23.84M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $12.29M derived: sum of 2 quarters · filed 2025-03-28 | $18.49M derived: sum of 3 quarters · filed 2025-03-28 | $24.35M 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | $5.96M 10-Q · filed 2024-11-06 | $12.16M derived: sum of 2 quarters · filed 2024-11-06 | $18.03M 10-Q · filed 2024-11-06 | $23.25M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $6.20M 10-Q · filed 2024-08-07 | $12.07M 10-Q · filed 2024-08-07 | $17.30M derived: sum of 3 quarters · filed 2024-08-07 | $21.54M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $5.87M 10-Q · filed 2024-05-08 | $11.09M derived: sum of 2 quarters · filed 2024-05-08 | $15.34M derived: sum of 3 quarters · filed 2024-05-08 | $18.78M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $5.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $9.47M derived: sum of 2 quarters · filed 2024-03-13 | $12.91M derived: sum of 3 quarters · filed 2024-03-13 | $15.22M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $4.25M 10-Q · filed 2023-11-08 | $7.68M derived: sum of 2 quarters · filed 2023-11-08 | $9.99M 10-Q · filed 2023-11-08 | $23.87M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-06-30 | $3.44M 10-Q · filed 2023-08-09 | $5.74M 10-Q · filed 2023-08-09 | $19.62M derived: sum of 3 quarters · filed 2024-03-13 | $19.62M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-03-31 | $2.31M 10-Q · filed 2023-05-10 | $16.19M derived: sum of 2 quarters · filed 2024-03-13 | $16.19M derived: sum of 3 quarters · filed 2024-03-13 | $16.19M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2021-12-31 | $14.00M 10-Q · filed 2022-08-10 | $13.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $13.88M derived: sum of 2 quarters · filed 2024-03-13 | $13.88M derived: sum of 3 quarters · filed 2024-03-13 | $14.00M 10-K · filed 2024-03-13 | $1.12M 10-K · filed 2022-03-17 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $120.00K 10-Q · filed 2022-11-09 | $13.69M derived: sum of 4 quarters · filed 2023-03-29 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | $120.00K 10-Q · filed 2022-08-10 | $13.69M derived: sum of 3 quarters · filed 2023-03-29 | $13.92M derived: sum of 4 quarters · filed 2023-03-29 | ||||
| 2021-03-31 | $120.00K 10-Q · filed 2022-05-12 | $13.69M derived: sum of 2 quarters · filed 2023-03-29 | $13.92M derived: sum of 3 quarters · filed 2023-03-29 | $28.92M derived: sum of 4 quarters · filed 2023-03-29 | ||||
| 2020-12-31 | $14.00M 10-K · filed 2025-03-28 | $13.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $13.80M derived: sum of 2 quarters · filed 2023-03-29 | $28.80M derived: sum of 3 quarters · filed 2023-03-29 | $14.00M 10-K · filed 2023-03-29 | $15.00M 10-K · filed 2021-03-11 | ||
| 2020-09-30 | $231.00K 10-Q · filed 2021-11-10 | $0.00 10-Q · filed 2020-11-10 | $15.23M derived: sum of 2 quarters · filed 2021-11-10 | $431.00K 10-Q · filed 2021-11-10 | $15.00M 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $15.00M 10-Q · filed 2021-08-11 | $15.00M 10-Q · filed 2021-08-11 | ||||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 | |||||||
| 2018-12-31 | $2.14K 10-K · filed 2020-03-16 | $18.82M derived: sum of 2 quarters · filed 2020-03-16 | $20.16M derived: sum of 3 quarters · filed 2020-03-16 | $20.16M 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $18.82M 10-K · filed 2020-03-16 | $20.16M derived: sum of 2 quarters · filed 2020-03-16 | $20.16M 10-Q · filed 2019-11-07 | |||||
| 2018-06-30 | $1.33M 10-K · filed 2020-03-16 | $1.33M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |